Article citationsMore>>

Kudo, M., Finn, R.S., Qin, S., Han, K., Ikeda, K., Piscaglia, F., et al. (2018) Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. The Lancet, 391, 1163-1173.
https://doi.org/10.1016/s0140-6736(18)30207-1

has been cited by the following article:

• TITLE: Conversion Therapy and Liver Regeneration in Liver Cancer

  AUTHORS: Xiaoqin Wu

  KEYWORDS: Liver Cancer, Conversion Therapy, Liver Regeneration

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.12, December 24, 2025

  ABSTRACT: This paper provides a narrative review of the primary modalities of conversion therapy for liver cancer, analyzes the characteristics and applications of different treatment approaches, and focuses on exploring the relationship between conversion therapy and liver regeneration, aiming to offer insights for optimizing conversion therapy strategies for liver cancer.